Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 43 versus ULTRAVIST 300 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 43 versus ULTRAVIST 300 IN PLASTIC CONTAINER.
CONRAY 43 vs ULTRAVIST 300 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
Iopromide is a nonionic, low-osmolality iodinated contrast medium that attenuates X-rays due to its iodine content (300 mg iodine/mL). It provides radiographic contrast in vascular and parenchymal imaging by increasing the density of blood vessels and tissues, thereby enhancing the visibility of structures and lesions.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
Intravenous administration of 1-2 mL/kg (300 mg iodine/mL) for contrast-enhanced CT; typical adult dose 100-150 mL (30-45 g iodine) given as bolus or rapid infusion.
None Documented
None Documented
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Terminal half-life: 2 hours in patients with normal renal function; prolonged up to 30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Renal: 90% unchanged via glomerular filtration within 24 hours; biliary: <1%; fecal: <2%.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent